Elevated mepolizumab levels in patients with severe asthma responsive to 1 year's mepolizumab treatment.

ABSTRACT:

Background

Asthma involves variable airflow limitation and persistent airway inflammation. Eosinophilic asthma, characterized by cytokine-mediated type 2 inflammation, is generally treated with inhaled corticosteroids. However, patients with severe asthma may require biologics, such as mepolizumab, which targets IL-5 and can manage uncontrolled eosinophilic asthma.

Objective

We investigated the relationship between serum mepolizumab concentrations and treatment response in patients with severe asthma.

Methods

Patients with mepolizumab-treated severe asthma were enrolled onto this prospective cohort study. Baseline assessments were conducted and repeated at 3, 6, and 12 months. Those with response were categorized on the basis of improvements in asthma control test sco

SUBMITTER: Nishimaki T 

PROVIDER: S-EPMC11836490 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature